Cargando…
Loading, please waitCargando…
Loading, please waitConditions
Lupus is a serious, lifelong autoimmune disease. The cornerstone of care is a rheumatologist and disease-modifying medication — regenerative protocols are only an investigational adjunct that we coordinate around your treating physician, never a replacement.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system loses tolerance to the body's own tissues, producing autoantibodies that can attack the skin, joints, kidneys, blood, heart, lungs and central nervous system. Disease activity typically fluctuates between flares and periods of remission.
Lupus affects women approximately nine times more often than men, with onset most common between ages 15 and 45. It is more frequent and tends to be more severe in people of Latin American, African and Asian descent. Worldwide prevalence is estimated at around 30 to 50 cases per 100,000 people, with higher figures in Hispanic populations in the Americas.
Because lupus can involve multiple organ systems, care must be coordinated by a rheumatologist who monitors disease activity with clinical exams, autoantibody panels (ANA, anti-dsDNA, complement C3/C4), kidney function and imaging. Treatment usually combines hydroxychloroquine, corticosteroids, conventional immunosuppressants (e.g. mycophenolate, azathioprine, methotrexate) and, in selected cases, biologic therapies.
At Regeneris Therapy in Cancún we do not replace this medical framework. When appropriate and after written authorization from your rheumatologist, mesenchymal stem cell (MSC) therapy and supportive protocols may be considered as an investigational adjunct aimed at modulating inflammation and improving quality of life. Every case is evaluated honestly, and many patients are respectfully redirected when adjunctive therapy is not the right fit.
Lupus is multifactorial. There is no single trigger; it arises from a combination of genetic susceptibility, hormonal influences, environmental exposures and immune dysregulation. First-degree relatives of patients have a higher risk, and over a hundred genetic variants — particularly in HLA, complement and interferon-pathway genes — have been linked to the disease.
Female sex hormones (estrogens) appear to amplify autoimmunity, which helps explain the 9:1 female-to-male ratio and onsets near puberty, pregnancy and the perimenopausal transition. Environmental triggers include ultraviolet (sun) exposure, viral infections such as Epstein-Barr virus, silica dust, cigarette smoke and certain medications (drug-induced lupus).
At the cellular level, hyperactive B cells produce autoantibodies, T cells lose self-tolerance, and the type-I interferon pathway is chronically overexpressed. Immune complexes deposit in tissues and complement activation drives the organ damage characteristic of lupus nephritis, vasculitis, serositis and CNS involvement.
Knowing the cause does not change first-line treatment — disease-modifying medication remains essential — but it informs why supportive strategies (sun protection, smoking cessation, sleep, stress management and nutrition) are integral to long-term control.
We want to be unambiguous: mesenchymal stem cell (MSC) therapy is not a cure for lupus and is not a replacement for hydroxychloroquine, corticosteroids, immunosuppressants or biologic therapy. At Regeneris Therapy we only consider it as an investigational, supportive option for patients whose lupus is already stable on standard care and whose rheumatologist agrees in writing.
The scientific rationale is the documented immunomodulatory effect of MSCs: they can reduce activated T-cell proliferation, lower autoantibody production, dampen the type-I interferon signature and shift the cytokine balance toward regulatory T cells. Small-to-medium clinical trials in refractory lupus have reported reductions in SLEDAI disease-activity scores and steroid-sparing effects in selected patients, although evidence remains preliminary and individual response varies.
Our protocols are intravenous, COFEPRIS-traceable allogeneic umbilical-cord-derived MSCs from licensed Mexican laboratories. They are never applied during an active flare; we wait for clinical and serological stabilization, confirmed by your rheumatologist. We also do not treat severe organ involvement (active nephritis with significant proteinuria, CNS lupus, severe cytopenias) — those situations require hospital-based specialist care first.
Supportive IV therapy (vitamins, antioxidants, NAD+) may complement standard care for fatigue, sleep and energy, also as an adjunct only. We coordinate every step with your rheumatologist and document all interventions in your medical record.
Lupus is a lifelong condition. With modern rheumatologic care and consistent adherence, ten-year survival now exceeds 90 percent in most cohorts, and many patients reach long periods of low disease activity or remission. Outcomes depend strongly on early diagnosis, kidney involvement, adherence to medication and lifestyle factors such as sun protection and smoking cessation.
Flares can be unpredictable, which is why disease-modifying medication is usually maintained even during quiet periods. The goal is sustained remission with the lowest effective steroid dose. Regenerative protocols, when used at all, are framed as supportive — they do not change disease trajectory, do not allow medication to be stopped, and do not eliminate the need for routine rheumatologic monitoring.
Honest expectation-setting is part of our model. We will tell you directly when adjunctive therapy is unlikely to add value, and we will redirect you to your treating physician when standard care needs to be optimized first.
No. This is the single most important point on this page. Stem cell therapy does not replace hydroxychloroquine, corticosteroids, mycophenolate, azathioprine, methotrexate, rituximab, belimumab or any other prescribed lupus medication. Stopping or reducing these medicines without your rheumatologist's guidance can trigger severe flares, kidney damage and life-threatening complications. We will not offer a regenerative protocol to anyone who is using it as a reason to stop standard treatment.
Revisado por Dra. Claudia Labastida · 2026-05-18
Not at this time. During an active flare the immune system is highly inflamed and additional cellular interventions are not appropriate. We require clinical and serological stabilization, confirmed by your treating rheumatologist, before considering any adjunctive protocol. This is a safety boundary we do not cross.
Revisado por Dra. Claudia Labastida · 2026-05-18
There is preliminary evidence from small and medium-sized clinical trials — mostly in patients with refractory disease — showing reductions in SLEDAI scores, lower steroid requirements and improvements in quality of life. Evidence is not yet sufficient to consider MSC therapy a standard of care for lupus, and we present it to patients as investigational. Larger randomized trials are still needed.
Revisado por Dra. Claudia Labastida · 2026-05-18
Yes, always. Your rheumatologist remains in charge of your lupus. We do not order or interpret your routine disease-activity panels, kidney function or imaging — those belong with your specialist. Our role is strictly adjunctive, and we share documentation with your physician so your care stays integrated.
Revisado por Dra. Claudia Labastida · 2026-05-18
In most stable patients, yes, but timing matters. We review your full medication list, recent labs and disease activity before recommending a session, and we coordinate with your rheumatologist to choose a window that does not interfere with infusions of rituximab, belimumab or other agents. We do not change your prescribed regimen.
Revisado por Dra. Claudia Labastida · 2026-05-18
No. Active lupus nephritis with significant proteinuria, biopsy-confirmed class III/IV/V disease, central-nervous-system lupus, severe cytopenias or antiphospholipid-syndrome complications require hospital-based specialist treatment. We will tell you directly when your situation is outside our scope and help you stay focused on the team that can manage it safely.
Revisado por Dra. Claudia Labastida · 2026-05-18
Pregnancy in lupus requires planning with your rheumatologist and a high-risk obstetrician. We do not offer regenerative protocols during pregnancy or active conception planning. Maintaining your prescribed medication regimen during pregnancy is determined exclusively by your medical team.
Revisado por Dra. Claudia Labastida · 2026-05-18
The first step is a medical consultation with our physicians, with a copy of your recent rheumatology notes and labs. We will review your disease activity, organ involvement and current medication, contact your rheumatologist, and give you an honest answer — including a clear "not now" or "not at all" when that is the right call.
Revisado por Dra. Claudia Labastida · 2026-05-18
Scientific evidence
This bibliography is provided for educational purposes. It does not constitute medical advice and does not imply that any cited study endorses Regeneris Therapy or guarantees a clinical outcome.
An honest medical review of mesenchymal stem cell therapy for SLE: immunomodulatory mechanisms, clinical evidence, ideal candidates, and COFEPRIS regulation.
An evidence-based overview of current research into mesenchymal stem cells and exosomes for autoimmune diseases, including lupus, rheumatoid arthritis, and multiple sclerosis.
Knee osteoarthritis (gonarthrosis, ICD-10 M17) is the progressive wear of the cartilage that covers the femur, tibia and patella. At Regeneris Therapy we combine current clinical evidence and regenerative medicine to reduce pain, improve mobility and, in selected cases, postpone or avoid total knee replacement.
Learn about Knee OsteoarthritisFibromyalgia is real, medical and deserves an honest approach. At Regeneris Therapy we combine regenerative medicine, IV therapy and an integrative protocol to help you recover energy, sleep and quality of life — always alongside your rheumatologist.
Learn about Fibromyalgia in Cancún: Symptoms, Causes and Regenerative OptionsAndrogenetic alopecia is the most common cause of progressive hair loss in men and women. Below we explain how it develops, what regenerative therapies can realistically offer, and how our physicians at Regeneris build a plan around your specific pattern of thinning.
Learn about Androgenetic Alopecia in Cancún: Causes and Regenerative OptionsNext step
If you live with lupus and want to understand whether supportive regenerative protocols could ever fit alongside your rheumatology care, book an honest medical consultation in Cancún. We coordinate with your treating physician and will only recommend an adjunct when it is safe and appropriate.